Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Laura Tullis

Nurse Practitioner, Gerontology Kansas City, MO Nurse Practitioner

NPI 1841651346 CMS profile 10712827

1000 Carondelet Dr Ste 201B, Kansas City, MO 64114

Open in the dashboard

General payments

$6,670

563 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Laura Tullis of Kansas City, MO is reported in the CMS Open Payments database as having received $6,670 across 563 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Nurse Practitioner, Gerontology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $47 2
2024 General $226 8
2023 General $1,950 150
2022 General $1,972 180
2021 General $2,475 223

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Laura Tullis
  • Nurse Practitioner, Gerontology median
  • Middle half of Nurse Practitioner, Gerontology
  • National median

In program year 2025, general payments to Laura Tullis were reported at $47. Among 4,139 Nurse Practitioner, Gerontology profiles paid that year, the median was $179 and the middle half received between $55 and $547.

Show as a table
Year Laura Tullis Nurse Practitioner, Gerontology median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $2,475 $133 $44–$396 $132
2022 $1,972 $142 $48–$452 $149
2023 $1,950 $158 $53–$482 $160
2024 $226 $171 $55–$533 $164
2025 $47 $179 $55–$547 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Janssen Pharmaceuticals, Inc $1,209 113 payments
  2. Boehringer Ingelheim Pharmaceuticals, Inc. $915 75 payments
  3. Amgen Inc. $684 38 payments
  4. Novartis Pharmaceuticals Corporation $639 113 payments
  5. Sanofi-Aventis U.S. LLC $443 29 payments
  6. Pfizer Inc. $352 27 payments
  7. Daiichi Sankyo Inc. $346 19 payments
  8. Bayer HealthCare Pharmaceuticals Inc. $317 14 payments
  9. Amarin Pharma Inc. $260 20 payments
  10. Kowa Pharmaceuticals America, Inc. $242 38 payments
  11. Other $1,263 77 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $6,670 563 payments
Products named General payments · program years 2021–2025
  1. XARELTO $1,209 113 payments
  2. JARDIANCE $915 75 payments
  3. Repatha $684 38 payments
  4. ENTRESTO $375 71 payments
  5. INJECTAFER $346 19 payments
  6. Kerendia $317 14 payments
  7. MULTAQ $308 20 payments
  8. Vascepa $260 20 payments
  9. Livalo $242 38 payments
  10. OPSUMIT $238 9 payments
  11. Other $2,360 205 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 7 drugs

Part D claims

107

Median for Nurse Practitioner: 389

Drug cost

$2,481

Median for Nurse Practitioner: $21,885

Branded share of claims

18.7%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Prasugrel Hcl Generic 17 $1,424
Torsemide Generic 15 $298
Amlodipine Besylate Generic 17 $177
Olmesartan Medoxomil Generic 11 $176
Clopidogrel Clopidogrel Bisulfate Brand 20 $173
Metoprolol Succinate Generic 16 $153
Atorvastatin Calcium Generic 11 $79

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BOTOX
  • AbbVie, Inc. $103
$103 — —
LEQVIO
  • Novartis Pharmaceuticals Corporation $49
$49 — —
CAMZYOS
  • E.R. Squibb & Sons, L.L.C. $45
$45 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

563 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Gerontology in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record